Affiliation:
1. Sociedade Brasileira de Nefrologia, Brasil
2. Sociedade Brasileira de Hepatologia, Brasil
3. Instituto Brasileiro do Fígado, Brasil
Abstract
Abstract Infection by the hepatitis C virus is more prevalent in patients on dialysis than in the general population in Brazil, and has been associated with worse outcomes. Current therapy for hepatitis C is highly effective, safe, and widely available in Brazil, with coverage provided to dialysis patients with chronic kidney disease, which makes the elimination of hepatitis C a viable target. The Brazilian Society of Nephrology, the Brazilian Society of Hepatology, and the Brazilian Liver Institute developed the “Brazilian Registry for the Elimination of Hepatitis C in Dialysis Units”. This project aims to identify, treat, and monitor the response to treatment of patients on chronic dialysis infected with the hepatitis C virus in Brazil. This article presents the issue and invites Brazilian nephrologists to rally around the achievement of a significant goal.
Reference11 articles.
1. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome;Choo QL;Science,1989
2. Press release: the Nobel Prize in Physiology or Medicine 2020;Alter HJ,2021
3. Global hepatitis report 2017,2017
4. Censo da SBN 2020,2020
5. Brazilian dialysis census: analysis of data from the 2009-2018 decade;Neves PMM;Braz J Nephrol,2020
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献